This study evaluated patient-reported outcomes (PROs) of Medicine Access Programmes (MAPs) for Australian metastatic breast cancer patients on ribociclib. Limited patient awareness of MAP enrolment was identified, emphasising the need for improved education and consent processes. Most patients expressed gratitude for accessing non-funded medications and perceived enhanced medication adherence as a key benefit. Integrating PRO data with real-world registry data provides comprehensive insight for future MAP development.

Download full-text PDF

Source
http://dx.doi.org/10.1111/imj.16536DOI Listing

Publication Analysis

Top Keywords

medicine access
8
access programmes
8
metastatic breast
8
breast cancer
8
programmes patients
4
patients patient-reported
4
patient-reported outcome
4
outcome study
4
study ribociclib
4
ribociclib metastatic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!